β-Lactam effects on mixed cultures of common respiratory isolates as an approach to treatment effects on nasopharyngeal bacterial population dynamics

PLoS ONE

Volumn 3, Issue 12, 2008, Pages

  Sevillano, David ^a   Aguilar, Lorenzo ^a   Alou, Luis ^a   Giménez, María José ^a   González, Natalia ^a   Torrico, Martha ^a   Cafini, Fabio ^a   Coronel, Pilar ^b   Prieto, José ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b Tedec Meiji Farma SA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFDITOREN; CLAVULANIC ACID; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; COMPARTMENT MODEL; CONCENTRATION RESPONSE; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; NASOPHARYNX; NONHUMAN; PHARMACODYNAMICS; POPULATION DYNAMICS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; CELL CULTURE; COMPUTER SIMULATION; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGY; RESPIRATORY TRACT INFECTION;

BACTERIA (MICROORGANISMS); HAEMOPHILUS INFLUENZAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CELLS, CULTURED; CLAVULANIC ACID; COMPUTER SIMULATION; HAEMOPHILUS INFLUENZAE; NASOPHARYNX; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 57449117954     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003846     Document Type: Article

References (40)

1. Brook I, Gober AE (2005) Recovery of potential pathogens and interfering bacteria in the nasopharynx of otitis media-prone children and their smoking and nonsmoking parents. Arch Otolaryngol Head Neck Surg 131: 509-512.
2. Sá-Leão R, Nunes S, Brito-Avô A, Alves CR, Carriço JÁ, et al. (2008) High rates of transmission of and colonization by Streptococcus pneumoniae and Haemophilus influenzae within a day care center revealed in a longitudinal study. J Clin Microbiol 46: 225-234.
3. Hammitt LL, Bruden DL, Butler JC, Baggett HC, Hurlburt DA, et al. (2006) Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 193: 1487-1494.
4. Murthy TF (2005) Haemophilus influenzae. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett principles and practice of infectious diseases, 6th ed. Philadelphia: Elsevier Churchill Livingstone. pp 2661-2669.
5. Smith-Vaughan HC, Leach AJ, Shelby-James TM, Kemp K, Kemp DJ, et al. (1996) Carriage of multiple ribotypes of non-encapsulated Haemophilus influenzae in aboriginal infants with otitis media. Epidemiol Infect 116: 177-183.
6. Musher DM (2005) Streptococcus pneumoniae. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett principles and practice of infectious diseases, 6th ed. Philadelphia: Elsevier Churchill Livingstone. pp 2392-2411.
7. Sá-Leão R, Tomasz A, Santos Sanches J, de Lencastre H (2002) Pilot study of the genetic diversity of the pneumococcal nasopharyngeal flora among children attending day care centers. J Clin Microbiol 40: 3577-3585.
8. Ekdahl K, Ahlinder I, Hansson HB, Melander E, Mølstad S, et al. (1997) Duration of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project. Clin Infect Dis 25: 1113-1117.
9. Melegaro A, Choi Y, Pebody R, Gay N (2007) Pneumococcal carriage in United Kingdom families: estimating serotype-specific transmission parameters from longitudinal data. Am J Epidemiol 166: 228-235.
10. Pérez-Trallero E, Garcia-de-la-Fuente C, Garcia-Rey C, Baquero F, Aguilar L, et al. (2005) Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 49: 1965-1972.
11. Garcia-Cobos S, Campos J, L-acazaro E, Román F, Cercenado E, et al. (2007) Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime. Antimicrob Agents Chemother 51: 2564-2573.
12. Bisno AL, Stevens D (2005) Streptococcus pyogenes. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett principles and practice of infectious diseases, 6th ed. Philadelphia: Elsevier Churchill Livingstone. pp 2362-2379.
13. Martin JM, Green M, Barbadora KA, Wald ER (2004) Group A streptococci among school-aged children: clinical characteristics and the carrier state. Pediatrics 114: 1212-1219.
14. Brook I (2001) The role of beta-lactamase producing bacteria and bacterial interference in streptococcal tonsillitis. Int J Antimicrob Agents 17: 439-442.
15. Brook I, Gober AE (2006) Recovery of interfering and beta-lactamase-producing bacteria from group A beta-haemolytic streptococci carriers and non-carriers. J Med Microbiol 55: 1741-1744.
16. Baquero F (2005) Evolution and the nature of time. Int Microbiol 8: 81-91.
17. Cafini F, Aguilar L, Sevillano D, Giménez MJ, Alou L, et al. (2008) Decrease in bacterial load versus resistance selection of pneumococcal subpopulations by β-lactam physiological concentrations over time: An in vitro pharmacodynamic simulation. Microbial Drug Res 14: 13-21.
18. Sevillano D, Aguilar L, Alou L, Giménez MJ, Echevarría O, et al. (2006) Effects of antimicrobials on the competitive growth of Streptococcus pneumoniae: a pharmacodynamic in vitro model approach to selection of resistant populations. J Antimicrob Chemother 58: 794-801.
19. Dabernat H, Delmas C, Seguy M, Pelissier R, Faucon G, et al. (2002) Diversity of beta-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae. Antimicrob Agents Chemother 46: 2208-2218.
20. Scriver SR, Walmsley SL, Kau CL, Hoban DJ, Brunton J, et al. (1994) Determination of susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their β-lactamases. Antimicrob Agents of Chemother 38: 1678-1680.
21. National Committee for Clinical Laboratory Standards (2003) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Growth Aerobically-Sixth Edition: Approved Standard M7-A6. Wayne, PA, USA: NCCLS.
22. Augmentin package insert. www.fda.gov.
23. Cefditoren package insert. www.fda.gov.
24. Torrico M, Aguilar L, González N, Giménez MJ, Echeverría O, et al. (2007) Influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/ 125 milligrams) against Haemophilus influenzae strains exhibiting an N526K mutation in the ftsI gene. Antimicrob Agents Chemother 51: 3699-3706.
25. Andrews JM (1999) Microbiological assays. In: Reeves DS, Wise R, Andrews JM, White LO, eds. Clinical Antimicrobial Assays, 1st edn. Oxford: Oxford University Press. pp 35-44.
26. Martín M, Aguilar L, Balcabao IP, Gómez-Lus ML, Dal-Rée R, et al. (1997) In-vitro pharmacodynamic simulation of clavulanic acid concentrations: effect on Staphylococcus aureus and Haemophilus influenzae beta-lactamase activity. J Antimicrob Chemother 39: 290-292.
27. Prieto J, Aguilar L, Giménez MJ, Toro D, Gómez-Lus ML, et al. (1998) In vitro activities of co-amoxiclav at concentrations achieved in human serum against the resistant subpopulation of heteroresistant Staphylococcus aureus: a controlled study with vancomycin. Antimicrob Agents Chemother 42: 1574-1577.
28. Clinical and Laboratory Standards Institute (2007) Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement, M100-S17. Wayne, PA, USA: CLSI.
29. Gillespie SH, Voelker LL, Dickens A (2002) Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microb Drug Resist 8: 79-84.
30. Rozen DE, McGee L, Levin BR, Klugman KP (2007) Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 51: 412-416.
31. Nuermberger EL, Bishai WR (2004) Antibiotic resistance in Streptococcus pneumoniae: what does the future hold?. Clin Infect Dis 38 Suppl 4: S363-371.
32. Brook I, Foote PA (2005) Efficacy of penicillin versus cefdinir in eradication of group A streptococci and tonsillar flora. Antimicrob Agents Chemother 49: 4787-4788.
33. Brook I, Gober AE (2006) Increased recovery of Moraxella catarrhalis and Haemophilus influenzae in association with group A beta-haemolytic streptococci in healthy children and those with pharyngo-tonsillitis. J Med Microbiol 55: 989-992.
34. Casey JR, Pichichero ME (2007) The evidence base for cephalosporin superiority over penicillin in streptococcal pharyngitis. Diagn Microbiol Infect Dis 57(3 Suppl): S39-45.
35. Bisno AL (2004) Are cephalosporins superior to penicillin for treatment of acute streptococcal pharyngitis?. Clin Infect Dis 38: 1535-1537.
36. Shulman ST, Gerber MA (2004) So what's wrong with penicillin for strep throat?. Pediatrics 113: 1816-1819.
37. Ball P, Baquero F, Cars O, File T, Garau J, et al. (2002) Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 49: 31-40.
38. Sevillano D, Aguilar L, Alou L, Giménez MJ, González N, et al. (2008) High protein binding and cidal activity against penicillin-resistant S. pneumniae: a cefditoren in vitro pharmacodynamic simulation. PLoS ONE 3: e2717.
39. Pichichero ME, Casey JR, Mayes T, Francis AB, Marsocci SM, et al. (2000) Penicillin failure in streptococcal tonsillopharyngitis: causes and remedies. Pediatr Infect Dis J 19: 917-923.
40. Stjernquist-Desatnik A, Holst E (1999) Tonsillar microbial flora: comparison of recurrent tonsillitis and normal tonsils. Acta Otolaryngol 119: 102-106.